Mostoles

• A Study to Learn About the Safety, Tolerability and Blood Levels of a Study Medicine (called sisunatovir) in Infants and Children with RSV L … Not authorised
  2023-504425-39-00 3 Respiratory Syncytial Virus (RSV) Infection
• Is antibiotic prophylaxis necessary in inguinal or femoral hernia repair for the prevention of surgical site infection in our environment? Pending
  2023-507319-36-00 5 Inguinal or femoral hernia
• A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending
  2024-515448-22-00 4 Parkinson
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• CLINICAL TRIAL WITH APROTININ IN THE ACUTE RESPIRATORY DISTRESS SYNDROME TREATMENT Pending
  2025-520826-39-00 5 ACUTE RESPIRATORY DISTRESS SYNDROME
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Optimizing Aspirin Use for Preeclampsia Prevention Pending
  2025-524646-94-00 11 Obstetrics – Preeclampsia
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A Study to Learn About Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants Recruiting
  2022-503070-36-00 5 2025-12-23 Group B streptococcus (GBS) disease
• Inhaled sedation in the critically ill patient Recruiting
  2024-518521-14-00 6 2025-10-17 Critical condition
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontin … Recruiting
  2024-514833-39-00 3 2024-12-16 Stress or mixed urinary incontinence in women over 50 years of age not
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting
  2023-507293-40-00 6 2024-04-11 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
• Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety o … Recruiting
  2023-505687-11-00 5 2024-02-06 Acute pain
• A study on the safety, and immunogenicity of a UTI vaccine in adults 18 through 64 years of age and clinical efficacy in females 18 through … Ended recruitment
  2024-519319-32-00 7 2025-08-27 Urinary Tract Infections
• AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI … Ended recruitment
  2023-505601-16-00 5 2025-04-22 Chronic Migraine
• Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers, … Ended recruitment
  2023-510465-10-00 4 2025-03-10 Meningococcal immunization
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended recruitment
  2023-503403-28-00 4 2022-11-25 treatment naïve patients with HR+/HER2-negative high-risk early breast
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended recruitment
  2024-517008-12-00 5 2022-10-14 Newly-diagnosed multiple myeloma (NDMM)
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre

Showing 1–24 of 49 trials